Illumina releases DRAGEN v4.0 secondary analysis platform

By The Science Advisory Board staff writers

July 27, 2022 -- Illumina has released Illumina Dynamic Read Analysis for Genomics (DRAGEN) v4.0 as its most accurate and comprehensive secondary analysis platform. The new features allow laboratories to expand capabilities in analysis in oncology, pharmacogenomics, single-cell sequencing, and population genomics.

The expanded suite of capabilities includes the following:

  • DRAGEN v4.0 enables the calling of 20 Tier 1 genes and supports the genotyping of complex pharmacogenetic (PGx) genes. It powers insights for optimal genotype and metabolism status.
  • DRAGEN v4.0 integrates Expansion Hunter v5 with an expanded catalog of short tandem repeat (STR) loci.
  • There is improved access to whole-genome sequencing, allowing researchers and labs to leverage the platform with low-pass sequencing data.
  • DRAGEN v4.0 introduces single-cell assay for transposase-accessible chromatin with sequencing (ATAC-Seq) and single-cell multinomics. The single-cell ATAC-Seq pipeline allows single-cell resolution profiling of chromatin accessibility.

Mouse DNA methylation array seeks to accelerate high-sample-throughput studies
Scientists have developed a mouse DNA methylation array that contains more than 296,000 probes and a murine methylome atlas of 1,239 diverse cell types,...
Illumina, Merck develop new oncology assay
Illumina codeveloped a research test with Merck that assesses a new genomic signature with its TruSight Oncology 500 assay.
Illumina highlights new product, presentations at AGBT meeting
Illumina is debuting a new product and sharing presentations at the Advances in Genome Biology and Technology (AGBT) General Meeting taking place June...
NanoString improves Illumina’s sequencing systems via data workflow
NanoString Technologies has released a cloud-based workflow to enable simplified data analysis for researchers using Illumina’s NextSeq 1000 and NextSeq...
Illumina and Deerfield Management enter into drug development partnership
Illumina and Deerfield Management have entered into a partnership to accelerate drug discovery and development using genetic technologies and artificial...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter